LUXLung6-open-paren-2-close-paren-_2A: LUXLung6(2), figure 2A

In raredd/kmdata: A Database of Reconstructed Individual Patient Level Data from Oncology Clinical Trials

LUXLung6(2), figure 2A

Description

Kaplan-Meier digitized data from LUXLung6(2), figure 2A (PMID 24439929). A reported sample size of 364 for a primary endpoint of PFS in lung cancer.

Usage

`LUXLung6(2)_2A`

Format

A data frame of 364 observations and 3 variables:

	time	event time (in months)
	event	PFS event indicator (0: no event, 1: event)
	arm	treatment arms (afatinib, gemcitabine_cisplatin)

Source

Wu Y-L, Zhou C, Hu C-P, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014; 15: 213–22.

Examples

summary(`LUXLung6(2)_2A`)

kmplot(`LUXLung6(2)_2A`)

raredd/kmdata documentation built on June 15, 2025, 9:33 a.m.